CathVision Announces Launch of Clinical Study Evaluating Signal Complexity Algorithm
November 4, 2022 – CathVision, a medical technology company developing innovative electrophysiology solutions to improve clinical decision-making in the EP laboratory, today announced the study of the Signal Complexity algorithm designed to visualize and quantify the Atrial fibrillation (AF) complexity parameters in patients with persistent AF. Ten patients have been treated to date at NYU Langone Health, one of the nation’s leading academic medical centers.
CathVision’s CARDIALYTICS suite of artificial intelligence-based analytics, currently in development, will provide automated analysis designed to improve ablation outcomes using high-quality signal data from the ECGenius system. The NYU Langone study evaluating the Signal Complexity analysis tool is the second study launched to evaluate CARDIALYTICS algorithms. Last year, the PVISION study evaluated the PVI Analyzer algorithm developed to automate the assessment of pulmonary vein isolation.
“The ECGenius System acquires high-fidelity, low-noise cardiac signals. It is signal quality that drives the algorithms, giving physicians the ability to determine complex, personalized ablation strategies with greater confidence,” said Mads Matthiesen, CEO of CathVision. “We have developed the CARDIALYTICS suite of analytical tools, based on AI algorithms, to extend the benefits of the ECGenius system and create a solution tailored to the challenges physicians face in treating the complex population of patients with FA. Higher quality signals aligned with automated, intelligent analysis – this is the future of ablation therapy.
The Signal Complexity study is the fourth clinical study conducted by CathVision in the past 18 months. CathVision invests significantly in research and development as part of the company’s commitment to driving innovation in a field that has been stagnant for decades. Clean, clear signals obtained through advanced EP recording technology can improve the accuracy and efficiency of cardiac ablation procedures, potentially reducing the economic burden of atrial fibrillation and improving patient well-being.
“Current AF treatment requires multiple procedural ablation steps. We are in an age where advanced signal analytics, AI algorithms, and high signal quality can provide valuable visualization to analyze progress while throughout the ablation procedure,” said Dr. Larry Chinitz, Alvin Benjamin, and Kenneth Coyle, Sr. Family Professor of Medicine and Cardiac Electrophysiology and Director of the Center for Cardiac Electrophysiology and Heart Rhythm in the Department of Medicine from the Leon H. Charney Division of Cardiology at NYU Langone.” The results obtained after applying the Signal Complexity algorithm to our case data support this notion, so we are excited to see what happens in the future. for the treatment of AF.”
For more information: www.cathvision.com
 The ECGenius System is authorized for sale in the United States. Note CARDIALYTICS is not authorized for sale in the United States.